Febuxostat Versus Allopurinol Use in Gout Patients: A Real-World Study

Area of Science:

• Rheumatology
• Cardiology
• Epidemiology

Background:

• Gout is a common condition requiring uric acid-lowering treatment.
• Cardiovascular events are a significant concern in gout patients.
• Understanding the comparative safety of gout medications is crucial.

Purpose of the Study:

• To conduct an epidemiological observation of a gout patient cohort.
• To characterize cardiovascular events and mortality in gout patients receiving allopurinol, febuxostat, or no uric acid-lowering treatment.
• To analyze the impact of comorbidities and co-medications on outcomes.

Main Methods:

• Observational study of 208 gout patients.
• Follow-up period averaged 4.8 years.
• Association study based on primary uric acid-lowering medication use (≥60% of follow-up).

Main Results:

• 18.1% of febuxostat users and 7.5% of allopurinol users experienced cardiovascular events.
• Mortality rates were 6.9% for febuxostat and 6% for allopurinol users.
• Higher prevalence of risk factors was noted in the febuxostat group.

Conclusions:

• The febuxostat group had more cardiovascular events, linked to a higher prevalence of risk factors.
• Interpreting these findings requires careful consideration due to common clinical scenarios.
• Individualized patient assessment is essential when choosing gout treatment.